🎗️ Oncology Papers

Scholarly works matching "oncology" in Crossref, sorted by the number of times other DOI-registered works cite them. Citation counts come from Crossref and are usually lower than Google Scholar figures.

575 top-cited papers indexed

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

Daniel Y. Wang, Joe-Elie Salem et al. (2018)

JAMA Oncology

2.5K citesjournal articlePDF

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke, Chafika Mazouni et al. (2008)

Journal of Clinical Oncology

2.4K citesjournal articlePDF

Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

Philip J. Johnson, Sarah Berhane et al. (2015)

Journal of Clinical Oncology

2.5K citesjournal articlePDF

Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

Bruce D. Cheson, John M. Bennett et al. (2003)

Journal of Clinical Oncology

2.4K citesjournal articlePDF

Epidemiology of Prostate Cancer

Prashanth Rawla (2019)

World Journal of Oncology

2.5K citesjournal articlePDF

Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index

Lisa Martin, Laura Birdsell et al. (2013)

Journal of Clinical Oncology

2.5K citesjournal articlePDF

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

Robert H.I. Andtbacka, Howard L. Kaufman et al. (2015)

Journal of Clinical Oncology

2.4K citesjournal articlePDF

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S Weber, Sandra P D'Angelo et al. (2015)

The Lancet Oncology

2.4K citesjournal articlePDF

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J Mufti et al. (2009)

The Lancet Oncology

2.4K citesjournal articlePDF

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial

Ethan Basch, Allison M. Deal et al. (2016)

Journal of Clinical Oncology

2.4K citesjournal articlePDF

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

Quinn T Ostrom, Gino Cioffi et al. (2019)

Neuro-Oncology

2.4K citesjournal articlePDF

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

Silvia de Sanjose, Wim GV Quint et al. (2010)

The Lancet Oncology

2.3K citesjournal articlePDF

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gunter von Minckwitz, Michael Untch et al. (2012)

Journal of Clinical Oncology

2.3K citesjournal articlePDF

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

P McLaughlin, A J Grillo-López et al. (1998)

Journal of Clinical Oncology

2.2K citesjournal articlePDF

Oligometastases.

S Hellman, R R Weichselbaum (1995)

Journal of Clinical Oncology

2.3K citesjournal articlePDF